Showing 7131-7140 of 9283 results for "".
- New App Helps Physicians and Patients Take Control of Contact Dermatitishttps://practicaldermatology.com/news/20120820-new_app_helps_physicians_and_patients_take_control_of_contact_dermatitis/2459751/
- Low Cancer Risk Associated with UVA Nail Lampshttps://practicaldermatology.com/news/20120720-low_cancer_risk_associated_with_uva_nail_lamps/2459767/UVA lamps used for curing gel nails pose a very low risk for development of squamous cell carcinoma (SCC) on the dorsum of hands, new research suggests. (Br J Dermatol, E-pub). In fact, researchers say that only one woman in tens of thousands using UVA lamps over a number of years will develop SCC a
- Interactive Education Resource for Residents Now Availablehttps://practicaldermatology.com/news/20120716-interactive_education_resource_for_residents_now_available/2459772/
- Leading Melanoma Groups Unveil New Campaign Aimed at Menhttps://practicaldermatology.com/news/20120515-leading_melanoma_groups_unveil_new_campaign_aimed_at_men/2459800/
- Health Canada Approves BMS' Yervoy forhttps://practicaldermatology.com/news/20120208-health_canada_approves_bms_yervoy_for/2459870/
- CLL Linked to Higher Skin Cancer Risk and Worse Outcomes in Nationwide Studyhttps://practicaldermatology.com/news/cll-linked-to-higher-skin-cancer-risk-and-worse-outcomes-in-nationwide-study/2486526/Patients with chronic lymphocytic leukemia (CLL) face a significantly elevated risk of developing skin cancer, according to a nationwide Danish cohort study spanning three decades. Study investigators analyzed registry data fr
- Icotrokinra Shows Sustained Skin Clearance Through 52 Weeks in Psoriasishttps://practicaldermatology.com/news/icotrokinra-shows-sustained-skin-clearance-through-52-weeks-in-psoriasis/2486494/New 52-week data presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting highlight the sustained efficacy and safety of icotro
- Phase 3 Data Highlight Early and Broad Response With Deuruxolitinibhttps://practicaldermatology.com/news/phase-3-data-highlight-early-and-broad-response-with-deuruxolitinib/2486483/Two posters presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting provide complementary Phase 3 evidence supporting the efficacy of deuruxolitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, in adults with severe alopecia areata (AA). Both analyses pooled data from th
- Nicotinamide Linked to Reduced Melanoma Risk in VA Cohorthttps://practicaldermatology.com/news/nicotinamide-linked-to-reduced-melanoma-risk-in-va-cohort/2486445/Nicotinamide exposure was associated with a 25% reduction in melanoma incidence in a large VA cohort, according to data from a retrospective cohort study presented at the 2026 American Academy of Dermatology Annual Meeting. Investigators analyzed 30,741 pati
- Nail Psoriasis and Real-World Data Highlight Tildrakizumab’s Staying Powerhttps://practicaldermatology.com/news/nail-psoriasis-and-real-world-data-highlight-tildrakizumabs-staying-power/2486482/Two posters presented at the American Academy of Dermatology (AAD) Annual Meeting highlight both clinical trial efficacy and real-world durability of tildrakizumab, an interleukin (IL)-23 p19 inhibitor, in patients with moderate-to-severe plaque psoriasis.